All articles by Fiona Barry
Fiona Barry is an Associate Editor responsible for GlobalData PharmSource’s editorial content. She previously worked as an investigative journalist reporting scoops on drug trials, contract pharma, rare diseases, and women’s health.
Fiona Barry
CMO Moves: Regulatory catalysts for drug manufacturing – March 2023
Pharmaceutical Technology analyses recent regulatory and trial announcements that are likely to impact therapy manufacturing plans.
CMO Moves: Regulatory catalysts for drug manufacturing- February
Pharmaceutical Technology analyses recent regulatory announcements that will likely impact therapy manufacturing plans.
Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict
EFPIA, the trade organisation for branded drugs, said the proposals ‘would irretrievably sabotage’ the EU pharma industry.
CMO Moves: Regulatory catalysts for therapy manufacturing -January
Pharmaceutical Technology analyses recent regulatory announcements that will likely impact therapy manufacturing plans.
CMO Moves: Regulatory catalysts for drug manufacturing-December
Pharmaceutical Technology analyses recent trial and regulatory-related announcements that will likely impact therapy manufacturing plans.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
CMO Moves: Regulatory catalysts for drug manufacturing-November
Pharmaceutical Technology analyzes recent regulatory decisions by several authorities that will likely impact therapy manufacturing plans.
CMO Moves: Regulatory catalysts for drug manufacturing-October
Pharmaceutical Technology analyses recent regulatory decisions and trial results that are expected to impact therapy manufacturing plans.
CMO Moves: Regulatory catalysts for drug manufacturing-September
Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.
CMO Moves: Regulatory catalysts for drug manufacturing—August
Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.
California’s low-cost insulin plans receive $100m manufacturing boost
Governor Newsom unveils plans to work with a CMO to produce low-cost insulin, even though most insulin is currently produced in-house by big pharma.